Equities research analysts expect Cara Therapeutics Inc (NASDAQ:CARA) to post sales of $5.14 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Cara Therapeutics’ earnings, with the highest sales estimate coming in at $6.00 million and the lowest estimate coming in at $4.00 million. The company is scheduled to announce its next earnings results on Wednesday, May 8th.

On average, analysts expect that Cara Therapeutics will report full-year sales of $21.50 million for the current year, with estimates ranging from $20.00 million to $24.00 million. For the next financial year, analysts expect that the firm will report sales of $23.47 million, with estimates ranging from $17.06 million to $30.30 million. Zacks’ sales averages are an average based on a survey of analysts that cover Cara Therapeutics.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.07. The firm had revenue of $5.53 million for the quarter, compared to analyst estimates of $3.35 million.

CARA has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 29th. Laidlaw set a $30.00 price objective on Cara Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 20th. Canaccord Genuity set a $25.00 price target on Cara Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 20th. BidaskClub upgraded shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd. Finally, Jefferies Financial Group began coverage on Cara Therapeutics in a research note on Wednesday, February 6th. They issued a “buy” rating and a $22.00 target price for the company. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $24.03.

NASDAQ:CARA traded down $0.87 during mid-day trading on Friday, hitting $19.47. 799,317 shares of the company’s stock were exchanged, compared to its average volume of 638,905. Cara Therapeutics has a fifty-two week low of $11.50 and a fifty-two week high of $24.30. The company has a market cap of $790.01 million, a PE ratio of -9.48 and a beta of 2.70.

In other news, CEO Derek T. Chalmers sold 20,000 shares of the stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $14.99, for a total value of $299,800.00. Following the transaction, the chief executive officer now directly owns 953,788 shares of the company’s stock, valued at $14,297,282.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Frederique Ph.D. Menzaghi sold 1,500 shares of the stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $17.50, for a total value of $26,250.00. Following the completion of the transaction, the senior vice president now directly owns 142,779 shares in the company, valued at $2,498,632.50. The disclosure for this sale can be found here. Insiders sold a total of 69,533 shares of company stock valued at $1,211,110 over the last quarter. Company insiders own 6.70% of the company’s stock.

A number of hedge funds have recently modified their holdings of CARA. ETF Managers Group LLC acquired a new position in shares of Cara Therapeutics during the fourth quarter valued at approximately $7,624,000. BlackRock Inc. boosted its position in shares of Cara Therapeutics by 23.1% during the third quarter. BlackRock Inc. now owns 2,758,118 shares of the biopharmaceutical company’s stock worth $66,055,000 after buying an additional 516,870 shares during the period. Vanguard Group Inc boosted its position in shares of Cara Therapeutics by 24.5% during the third quarter. Vanguard Group Inc now owns 1,551,344 shares of the biopharmaceutical company’s stock worth $37,155,000 after buying an additional 305,020 shares during the period. Vanguard Group Inc. boosted its holdings in Cara Therapeutics by 24.5% in the third quarter. Vanguard Group Inc. now owns 1,551,344 shares of the biopharmaceutical company’s stock valued at $37,155,000 after purchasing an additional 305,020 shares during the period. Finally, Nexthera Capital LP boosted its holdings in Cara Therapeutics by 69.2% in the third quarter. Nexthera Capital LP now owns 737,303 shares of the biopharmaceutical company’s stock valued at $17,658,000 after purchasing an additional 301,503 shares during the period. Institutional investors own 61.33% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Get a free copy of the Zacks research report on Cara Therapeutics (CARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.